Inclusion Criteria:

- Patients with histologically-confirmed, advanced unresectable solid tumors
Availability of a representative formalin fixed paraffin embedded tumor tissue sample

- At least one measurable or non-measurable lesion Age ≥ 18 years

- Eastern Cooperative Oncology Group(ECOG) Performance Status ≤ 2 Good organ (hepatic,
kidney, BM) function at screening/baseline visit

Exclusion Criteria:

- Brain metastasis unless treated and free of signs/symptoms attributable to brain
metastasis in the absence of corticosteroid therapy and anti-epileptic therapy.

- Prior treatment with PI3K inhibitor

- Patient with peripheral neuropathy NCI-CTC Grade ≥ 2

- Patient with diarrhea NCI-CTC Grade ≥ 2

- Patient with acute or chronic pancreatitis

- Impaired cardiac function or clinically significant cardiac disease incl unstable
angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial
Infarction (AMI) ≤ 3 months prior to starting study drug

- Patients with clinically manifest diabetes mellitus, history of gestational diabetes
mellitus or documented steroid-induced diabetes mellitus

- Women who are pregnant or breast feeding or adults of reproductive potential not
employing an effective method of birth control

Other protocol-defined inclusion/exclusion criteria may apply